Response to Schmidt et al.: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis
2024
CETP Inhibition and Dementia Risk
publication
Evidence: moderate
Author Information
Author(s): Emma L. Anderson
Primary Institution: University College London
Hypothesis
Is CETP inhibition a viable target for treating dementia?
Conclusion
CETP inhibition is unlikely to be a viable target to treat the most prevalent causes of dementia.
Supporting Evidence
- CETP inhibition may reduce risk of any stroke, but little evidence supports its effect on dementia.
- Previous studies showed little evidence of CETP inhibition affecting Alzheimer's risk.
- Recent GWAS meta-analyses provide larger sample sizes for more precise results.
Takeaway
Scientists looked at whether blocking a protein called CETP could help with dementia, but they found it might actually make Alzheimer's disease worse.
Methodology
The study used Mendelian randomization to examine the effects of CETP inhibition on dementia risk.
Limitations
The study did not consider Alzheimer's disease as an outcome despite its prevalence.
Statistical Information
Confidence Interval
OR: 0.99, 95% CI: 0.91–1.07
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website